WO1996026927A1 - Derives d'imidazole et composition medicinale a base desdits derives - Google Patents
Derives d'imidazole et composition medicinale a base desdits derives Download PDFInfo
- Publication number
- WO1996026927A1 WO1996026927A1 PCT/JP1996/000490 JP9600490W WO9626927A1 WO 1996026927 A1 WO1996026927 A1 WO 1996026927A1 JP 9600490 W JP9600490 W JP 9600490W WO 9626927 A1 WO9626927 A1 WO 9626927A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- methyl
- magnetic resonance
- nuclear magnetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a novel imidazole derivative which exhibits a steroid 17-20 lyase inhibitory activity and is useful as a medicament, in particular, a novel imidazole derivative having cataphoryl or fluorene or a salt thereof.
- the steroid 17-20 lyase is formed from cholesterol and has a carbon substituent at the 17; 9-position. It uses 17-hydroxypregnenolone and 17-hydroxyprogesterone as substrates, and the 17-carbon Cleaves the bond of the carbon substituent to the carbon at position 20 to form dehydroepiandrosterone and androstenedione, respectively.
- a compound that inhibits steroid 17-20 lyase is considered to be a drug that can completely block the action of androgen even in view of its action and can block total androgen, and is expected to be promising for the treatment of prostate cancer and the like. ing.
- steroid 17-20 lyase inhibitors can suppress the production of estrogen, they are more effective in treating benign prostatic hyperplasia than those that block only androgens, and have fewer side effects. Expected to be less drug.
- Non-steroidal steroid 17-lyase lyase inhibitors include, for example, substituted benzoimidazolyl groups and imidabryl groups described in JP-A-64-895975, in which methine carbon or methylene carbon is used. Bound (1H-imidabouryl-1-ylmethyl) -substituted benzimidavour derivatives are known.
- R 2 in the general formula (A) is a substituted or unsubstituted phenyl group, a substituted or unsubstituted bicyclic or tricyclic hydrocarbon ring group having a fused benzene ring, or an oxygen atom
- a substituted or unsubstituted bicyclic or tricyclic fused heterocyclic group having a heterocyclic ring having Z or a sulfur atom and a heteroatom having Z or a nitrogen atom and a fused benzene ring specifically, a carbazolyl group and a fluorene group.
- the compound had good activity in inhibiting steroid 17-lyase lyase in vitro, its pharmacological effect in vivo was still insufficient.
- the present inventors have completed the present invention by finding that 17-20 lyase inhibitory activity is excellent not only in in vitro but also in vivo.
- the present invention relates to an imidabule derivative represented by the following general formula (I), a salt thereof, a hydrate thereof or a solvate thereof.
- X a methylene group or a group represented by formula NR 2 — R 1 : hydrogen atom, lower alkyl group or aralkyl group
- R 2 hydrogen atom or lower alkyl group
- Preferred compounds in the compound (I) of the present invention include a compound characterized in that A is bonded at the 4- or 5-position of the imidabul ring, a salt thereof, a hydrate thereof or a solvate thereof; Bonds at the 2 or 3 position of the ring
- ⁇ is an unsubstituted or lower alkylene group substituted with an aryl or lower alkylidene group, an imidabul derivative, a salt thereof, a hydrate or a solvate thereof, particularly preferably A is unsubstituted or substituted with a lower alkylidene group.
- Lower alkylene group imidabul derivatives, salts, hydrates or solvates thereof
- Another object of the present invention is to provide a pharmaceutical composition containing the compound of the present invention, which comprises a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof as a steroid.
- a steroid 17-20 lyase inhibitor which is a preventive or therapeutic agent for diseases caused by increased androgen and Z or estrogen; Specifically, it is a steroid 17-20 lyase inhibitor that is a prophylactic and therapeutic agent for prostate cancer, benign prostatic hyperplasia, virilization, hirsutism, breast cancer, mastopathy, uterine fibroids, and endometriosis.
- lower means a straight or branched carbon chain having 1 to 6 carbon atoms.
- the “lower alkyl group” is specifically, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group , Tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 3,3-dimethylbutyl group, 1-ethylbutyl group , 2-Ethylbutyl group
- Specific examples of the lower alkylene group J include, for example, methylene group, ethylene group, methylmethylene group, trimethylene group, 1-methylethylene group, 2-methylethylene group, ethylmethylene group, tetramethylene group, 1-methyltrimethylene group.
- alkylene groups having 1 to 4 carbon atoms are preferred, and more preferred are a methylene group, a methylmethylene group, an ethylmethylene group, a propylmethylene group and an isopropylmethylene group.
- CH: methylidene group
- CH 3 —CH ethylidene group
- propylidene group a propylidene group.
- Group (CH 3 — CH 2 -CH ), pyridene group
- a lower alkylene group substituted with a lower alkylidene group is one in which two hydrogen atoms bonded to any carbon atom of the lower alkylene group have been replaced with a double bond of a lower alkylidene group, and preferably a vinylidene group.
- aryl group j means a carbon ring aryl, and specifically, a phenyl group, Examples include a biphenyl group or a naphthyl group, and a phenyl group is preferable. Accordingly, as a lower alkylene group which may be substituted with a hydroxyl group, an aryl group or an oxo group, specifically,
- hydroquine trimethylene group (one CH— CH 2 — CH 2 —,
- Preferred examples of the substituent of the “lower alkylene group” include a lower alkylidene group having 1 to 3 carbon atoms and a phenyl group.
- the “aralkyl group” means a group in which the above-mentioned aryl group is substituted at an arbitrary position of the lower alkyl group, and specifically includes a benzyl group, a phenyl group, a naphthylmethyl group and the like.
- the compound of the present invention may be capable of forming a salt with an inorganic acid or an organic acid, and such a salt also has a steroid 17-20 lyase inhibitory action like a free base.
- Suitable salts include, for example, inorganic acid salts such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid , Maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid and ethanesulfonic acid.
- salts with pharmaceutically acceptable alkaline metals or alkaline earth metals eg, sodium, potassium, magnesium, or calcium
- organic amines with ammonia, triethylamine, etc. May also be able to form salts.
- the compound of the present invention may have an asymmetric carbon atom depending on the type of the group A or the substituent described above. Such a compound has an optical isomer based on the asymmetric carbon atom, If it has the above asymmetric carbon atom, then diastereoisomers are present. In addition, there are geometric isomers (cis isomers, trans isomers) and tautomers based on double bonds. The present invention relates to isolated forms of these various isomers and mixtures of these isomers. Is included.
- the compounds of the present invention also include various hydrates, various solvates such as methanol and ethanol, tautomers, and polymorphs.
- the compounds of the present invention include isolated compounds of these compounds. And mixtures thereof.
- the reaction can be appropriately performed using a protecting group.
- a protecting group for example, when X is —NH—, one NP 1 — is used using the protecting group P 1 .
- the group P 1 means a general protecting group for an amino group, such as a benzyl group, a benzhydryl group, a trityl group, a benzyl-based protecting group such as 4-methoxybenzyl group, or a formyl group, an acetyl group or an acyl group such as a propionyl group.
- Aralkyloxycarbonyl groups such as benzyloxycarbonyl group, lower alkoxycarbonyl groups such as tert-butynecarbonyl group, sulfonyl groups such as tosyl group, benzenesulfonyl group, methanesulfonyl group, methoxymethyl group, tetrahydroviranyl
- Aminoacetal-type protecting groups such as trimethylsilyl groups; and trialkylsilyl groups such as tert-butyldimethylmethylyl groups.
- B an alkylene group having 1 to 5 carbon atoms which may be substituted by a single bond or an aryl group
- Benzyl protecting groups such as P 2 trityl group
- R 3 hydrogen atom, lower alkyl group or aryl group
- R 3 * -M Organic such as alkyl lithium, aryl lithium or Grignard reagent
- the halogen atom means a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- a halogen compound (II) is reacted with a metal reagent (such as alkyllithium such as n-butyllithium or metal magnesium).
- a metal reagent such as alkyllithium such as n-butyllithium or metal magnesium.
- an organometallic reagent obtained the reaction corresponding amount, preferably 1 to 2 equivalents of an aldehyde compound (III) and under cooling, preferably reacted under one 100-0 e C, 2 pole alcohol - Le ( IV).
- Second step In an organic solvent such as dichloromethane, dichloroethane, black form, THF, dioxane, benzene, etc., a secondary alcohol (IV) and an oxidizing agent (manganese dioxide, chromic acid, etc.) are used to carry out a conventional oxidation reaction.
- an organic solvent such as dichloromethane, dichloroethane, black form, THF, dioxane, benzene, etc.
- an oxidizing agent manganese dioxide, chromic acid, etc.
- the second and third steps are performed when R 3 is a lower alkyl group or an aryl group.
- the compound (la ') can be obtained by performing the deprotection reaction by treating under acidic conditions to obtain a secondary alcohol (I Va) or a tertiary alcohol (VI la) in the fourth step. .
- This production method obtains substituted imidabul (lb).
- First step In an organic solvent such as acetonitrile, THF, dimethylformamide (DMF), etc., the imidazole compound (Ia) and its corresponding amount, 1 to 5 equivalents of dimethylcarbamoyl chloride are reacted at room temperature to reflux temperature. This is the step of reacting to obtain the carbamoyl compound (VIII).
- organic solvent such as acetonitrile, THF, dimethylformamide (DMF), etc.
- Second step In an organic solvent such as acetonitrile, THF, DMF or the like, the reaction compound is reacted with a corresponding amount or an excess amount of an alkyl halide or an aralkyl halide (IX) at room temperature to reflux temperature to convert the oxime compound.
- This is the step of obtaining a substituted imidabule compound (lb) by reacting the ammonia compound with ammonia.
- P 3 protecting group such as alkylthio group, arylthio group, etc.
- R 4 hydrogen atom, lower alkyl group or aryl group
- Step 1 In an organic solvent such as THF, dioxane, getyl ether, and dimethoxetane, imidazole (X) protected with a protecting group such as an alkylthio group or an arylthio group is converted to a base (n-butyl).
- a protecting group such as an alkylthio group or an arylthio group
- Alkyl lithium such as lithium, lithium diiso
- a corresponding amount of the reaction 1-2 equivalents of aldehyde or ketone (XI) under cooling, preferably at 100 ° C.
- This is the step of reacting under 0'C to obtain protected imidazolyl-substituted alcohol (XII).
- 2nd step In an organic solvent such as methanol or ethanol, in the presence of Raney nickel or the like, at room temperature to reflux temperature, the protecting group of the imidabule ring of compound (XH) is removed to obtain an imidazolyl-substituted alcohol ( ⁇ ). .
- Second step In an organic solvent such as methanol, ethanol or acetic acid, imidazolyl-substituted alcohol (XH) is added to a catalyst (10% to 100% by weight) using a catalyst (10% palladium-carbon, palladium, palladium hydroxide, oxidation). (Palladium, platinum, platinum oxide, etc.) in a hydrogen atmosphere at room temperature to reflux temperature to obtain the compound of the present invention (Ic).
- XH imidazolyl-substituted alcohol
- the imidabril-substituted alcohol ( ⁇ ) is converted to a reaction equivalent or an excess amount of a reducing agent such as trialkylene lanthanum.
- a reducing agent such as trialkylene lanthanum.
- This production method is a method for producing the compound (Ie) or (If) of the present invention having a lower alkylidene group.
- Compound (Ie) or (If) is prepared in an organic solvent such as methanol, ethanol, THF, dioxane, dichloromethane, dichloroethane, chloroform, benzene, acid or trifluoroacetic acid by the above-mentioned first method and third method.
- the tertiary alcohol (VII) or (XH) in the production method must be dehydrated under acidic conditions using hydrochloric acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, etc., and then the steps indicated in the respective production methods must be carried out if necessary. Is obtained by
- R 7 represents a lower alkyl group.
- Step 2 In an organic solvent such as THF, dioxane, dimethoxyethane, geethylether or benzene, the phosphonate (XV) and the corresponding amount of the reaction, 1-2 equivalents of the aldehyde compound ( ⁇ ) are combined with a base (hydrogen). of Natoriumu, hydrogenated force Riu ⁇ , Chikarari ⁇ tert butoxide, potassium piston trimethylsilyl ⁇ Mi de, n- butyl alkyllithium such as lithium, etc. Richiumua Mi de such as lithium diisopropyl amine de) presence, 0 e Celsius to This is a step of obtaining an olefin form (XVI) (including two geometric isomers) by reacting at a reflux temperature.
- organic solvent such as THF, dioxane, dimethoxyethane, geethylether or benzene
- 1-2 equivalents of the aldehyde compound ( ⁇ ) are combined with a base (hydr
- the olefin compound (XVI) obtained in the second step is acidified (hydrochloric acid, St acid, trifluoroacetic acid, p-acid) in an organic solvent such as methanol, ethanol, THF, dioxane, acetic acid, and trifluoroacetic acid.
- the reaction is carried out at room temperature to reflux temperature under the conditions to deprotect the imidazole ring.
- Step 4 This step is performed by a conventional catalytic hydrogenation method.
- an organic solvent such as methanol, ethanol, ethyl acetate, THF, and dioxane
- the olefin compound (XVII) obtained in the third step is treated with a catalyst (palladium, palladium hydroxide, palladium oxide, platinum, Reduction in the presence of platinum oxide or the like) to obtain the present compound (Id).
- a catalyst palladium, palladium hydroxide, palladium oxide, platinum, Reduction in the presence of platinum oxide or the like
- the compound (Id) can be obtained directly from the compound (XVI) by the fourth step without going through the third step.
- P 4 represents a protecting group such as a trimethylsilyl group.
- This production method is a separate production method of the compound of the present invention (Ig) having a methylene group.
- a Lewis acid catalyst such as titanium tetrachloride
- a halomethyl compound (XIV) and imidazole (XVI II) protected with a protecting group such as a trimethylsilyl group in an organic solvent such as chloroform are cooled to room temperature.
- Compound (Ig) can be obtained by reacting
- removal of the protecting group is carried out by a conventional method.
- oxidation reactions for example, oxidation reactions, reduction reactions, hydrolysis under acidic or basic conditions, and the like.
- the compound of the present invention thus produced is isolated and purified as a free compound, a salt thereof, a hydrate, various solvates, crystal polymorphs and the like.
- a pharmaceutically acceptable salt of the compound (I) of the present invention can also be produced by subjecting the compound to a conventional salt formation reaction.
- Simple ellipses are made by applying ordinary chemical operations such as extraction, fractional crystallization, and various types of fractional chromatography.
- optical isomers can be sterically selected by selecting an appropriate starting compound or by a racemic resolution method of the racemic compound (for example, a method of optically resolving a diastereomer salt with a general optically active acid). It can lead to chemically pure isomers.
- a racemic resolution method of the racemic compound for example, a method of optically resolving a diastereomer salt with a general optically active acid. It can lead to chemically pure isomers.
- the compound of the present invention has an effect of inhibiting the activity of steroid 17-20 lyase, which is an enzyme involved in producing androgen from cholesterol in vivo. Therefore, the compound of the present invention inhibits the synthesis of androgens and estrogens synthesized using androgens as substrates, whereby various diseases are exacerbated by these factors, such as prostate cancer, benign prostatic hyperplasia, and masculosis. It is useful as a preventive and therapeutic drug for hirsutism, hirsutism, breast cancer, mastopathy, uterine fibroids, and endometriosis.
- Testes were removed from 10-week-old male Wistar rats, homogenized, and microsomes were obtained by centrifugation.
- Add a mixed solvent of methanol and tetrahydrofuran (2: 3) 4001 centrifuge, centrifuge, and measure the radioactivity of the substrates and products (androstenedione and testosterone) in the supernatant.
- the inhibitory activity of the test compound on steroid 17-20 lyase was determined by high performance liquid chromatography (HPLC) with a detector. The results are shown in Table 1.
- the compound of the present invention has an excellent effect as compared with the control compound.
- Test drugs were orally administered to 10-week-old male Wistar rats. After a certain period of time from the administration of the drug, decapitated blood was collected, and the testosterone concentration in the obtained serum was measured with a radioisotope atsay to determine the testosterone synthesis inhibitory activity. As a result, the compound of the present invention showed a strong testosterone synthesis inhibitory activity.
- the test drug was orally administered daily to a 10-week-old male Wistar rat, and the prostate weight was measured 2 weeks later.
- the compound of the present invention showed a strong prostate weight reducing effect.
- the compound of the present invention has excellent steroid 17-20 lyase inhibitory activity at invitro and invivo. Further, the compound of the present invention is excellent in durability and enzyme specificity.
- compositions containing one or more of the compounds represented by the general formula (I) and pharmaceutically acceptable salts or hydrates thereof as active ingredients are commonly used. Tablets, powders, fine granules, granules, capsules, pills, liquids, injections, suppositories, etc. It is administered parenterally.
- the dosage is determined as appropriate depending on the individual case, taking into account symptoms, age of the subject of administration, gender, body weight, etc., but is usually 0.1 to 10 mg / day, preferably 0.1 mg / day for an adult. It is orally administered once to several times a day in the range of 1 to 10 mg, or parenterally in the range of 0.1 to 100 mg per day, once to several times a day. It is administered intravenously or for 1 hour to 24 hours daily. Of course, as mentioned above, the dosage varies under various conditions, so that an amount smaller than the above dosage range may be sufficient.
- the one or more active substances comprise at least one inert diluent, such as lactose, mannitol, glucose, hydroxybutyral cellulose, microcrystalline cellulose, starch, polyvinyl alcohol. Don, mixed with magnesium aluminate metasilicate and the like.
- the composition may be formulated in a conventional manner with additives other than inert diluents, such as lubricants such as magnesium stearate, disintegrants such as calcium cellulose glycolate, stabilizers such as lactose, A solubilizing agent such as formic acid or aspartic acid may be contained.
- Tablets or pills may be coated with a film of a gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, if necessary.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsifiers, solutions, suspensions, syrups, elixirs and the like; commonly used inert diluents, for example, purified Contains water and ethanol.
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, flavoring agents and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injections and physiological saline.
- Non-aqueous solutions and suspensions include, for example, There are vegetable oils such as propylene glycol, polyethylene glycol and olive oil, alcohols such as ethanol, and surfactants such as polysorbate 80 (trade name). Such compositions may also contain adjuvants such as preserving, wetting, emulsifying, dispersing, and stabilizing agents (eg, lactose) and solubilizing agents (eg, glumic acid, aspartic acid). May be. These can be sterilized, for example, by filtration through a bacteria-retaining filter, blending of a fungicide, or irradiation. They can also be used in the manufacture of sterile solid compositions which are dissolved in sterile water or sterile injectable solvents before use. BEST MODE FOR CARRYING OUT THE INVENTION
- the solution was poured into a 5% aqueous solution of citric acid, extracted with ethyl acetate, and the organic layer was washed with water and brine, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the residue was purified by silica gel column chromatography (eluted with chloroform-ethyl monoacetate) to give 4.69 g (7.11 mm 01) of the title compound as white crystals.
- Example 3 (a) The following compound of Example 3 (a) was obtained in the same manner as in Example 1 (a).
- Example 3 b) The following compound of Example 3 (b) was obtained in the same manner as in Example 1 (d). 9 1-benzenesulfonyl 3 -— (1H—imidavour-41-methyl)
- Example 3 (c) The following compound of Example 3 (c) was obtained in the same manner as in Example 1 (e).
- Example 4 (a) The following compound of Example 4 (a) was obtained in the same manner as in Example 1 (a).
- Example 5 (a) The following compound of Example 5 (a) was obtained in the same manner as in Example 1 (a).
- Example 5 (b) The following compound of Example 5 (b) was obtained in the same manner as in Example 1 (d).
- Example 8 (a) The following compound of Example 8 (a) was obtained in the same manner as in Example 7 (a).
- Example 8 (b) In the same manner as in Example 7 (b), the following compound of Example 8 (b) was obtained.
- Example 10 (a) The following compound of Example 10 (a) was obtained in the same manner as in Example 7 (a).
- Example 11 (a) The following compound of Example 11 (a) was obtained in the same manner as in Example 7 (a).
- Example 11 (b) In the same manner as in Example 7 (b), the following compound of Example 11 (b) was obtained.
- Example 11 The following compound of Example 11 (e) was obtained in the same manner as in Example 1 (e).
- Example 15 (a) The following compound of Example 15 (a) was obtained in the same manner as in Example 1 (a).
- Example 15 (b) The following compound of Example 15 (b) was obtained in the same manner as in Example 14 (b).
- Example 15 (c) The following compound of Example 15 (c) was obtained in the same manner as in Example 1 (e).
- Example 16 (a) The following compound of Example 16 (a) was obtained in the same manner as in Example 1 (c).
- Example 16 (b) The following compound of Example 16 (b) was obtained in the same manner as in Example 1 (d).
- Example 16 (c) The following compound of Example 16 (c) was obtained in the same manner as in Example 1 (e).
- Example 17 (a) The following compound of Example 17 (a) was obtained in the same manner as in Example 1 (c).
- Example 17 (b) The following compound of Example 17 (b) was obtained in the same manner as in Example 1 (d).
- Raw material compound 1- (9-tosyl- 9H-Irbabur-1-2-yl) 1-1- (1-trityl-1H-Imidaburu-41-yl)
- Example 18 (b) The following compound of Example 18 (b) was obtained in the same manner as in Example 1 (d).
- Example 21 (a) The following compound of Example 21 (a) was obtained in the same manner as in Example 1 (a).
- Example 21 (b) The following compound of Example 21 (b) was obtained in the same manner as in Example 1 (b).
- Example 21 (d) The following compound of Example 21 (d) was obtained in the same manner as in Example 1 (d).
- Example 21 (e) The following compound of Example 21 (e) was obtained in the same manner as in Example 1 (e).
- Example 22 (a) The following compound of Example 22 (a) was obtained in the same manner as in Example 1 (a).
- Example 22 (b) The following compound of Example 22 (b) was obtained in the same manner as in Example 1 (b).
- Example 24 (a) The compound of Example 24 (a) below was obtained in the same manner as in Example 1 (b).
- Example 24 (b) In the same manner as in Example 1 (c), the following compound of Example 24 (b) was obtained.
- Table 2 shows the chemical structural formulas of the compounds obtained in the above examples.
- bond position a means the bond position between the imidazole ring and A
- bond position b means the bond position between and.
- the tablets were coated in a coating apparatus (Freund Corporation) containing 20.3 g of hydroxypropyl methylcellulose, 62,000 2.8 g of polyethylene glycol, 11.2 g of titanium oxide and 0.7 g of talc. 350 g of the liquid was sprayed to give film-coated tablets with 5 mg per tablet.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ302392A NZ302392A (en) | 1995-03-01 | 1996-03-01 | Tricyclic substituted imidazole derivatives and medicaments thereof |
PL96322028A PL322028A1 (en) | 1995-03-01 | 1996-03-01 | Derivatives of imidazoles and pharmaceutic composition containing them |
AU48439/96A AU702406B2 (en) | 1995-03-01 | 1996-03-01 | Imidazole derivatives and medicinal composition thereof |
EP96904295A EP0820989A4 (en) | 1995-03-01 | 1996-03-01 | IMIDAZOLE DERIVATIVES AND MEDICINAL COMPOSITION BASED ON SAID DERIVATIVES |
MXPA/A/1997/006585A MXPA97006585A (en) | 1995-03-01 | 1997-08-28 | Derivatives of imidazol and medicinal composition of mis |
NO973980A NO973980L (no) | 1995-03-01 | 1997-08-29 | Imidazolderivater og medisinsk preparat |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/42067 | 1995-03-01 | ||
JP4206795 | 1995-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996026927A1 true WO1996026927A1 (fr) | 1996-09-06 |
Family
ID=12625750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/000490 WO1996026927A1 (fr) | 1995-03-01 | 1996-03-01 | Derives d'imidazole et composition medicinale a base desdits derives |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0820989A4 (ja) |
KR (1) | KR19980702319A (ja) |
CN (1) | CN1177350A (ja) |
AU (1) | AU702406B2 (ja) |
CA (1) | CA2213246A1 (ja) |
HU (1) | HUP9801158A3 (ja) |
NO (1) | NO973980L (ja) |
NZ (1) | NZ302392A (ja) |
PL (1) | PL322028A1 (ja) |
WO (1) | WO1996026927A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046186A1 (fr) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation |
US7183305B2 (en) | 2003-11-11 | 2007-02-27 | Allergan, Inc. | Process for the synthesis of imidazoles |
US7880017B2 (en) | 2003-11-11 | 2011-02-01 | Allergan, Inc. | Process for the synthesis of imidazoles |
US8080566B1 (en) | 2008-06-11 | 2011-12-20 | Kalypsys, Inc | Carbazole inhibitors of histamine receptors for the treatment of disease |
JP2014125444A (ja) * | 2012-12-26 | 2014-07-07 | Ne Chemcat Corp | カルバゾール類の製造方法およびこの方法により製造されたカルバゾール類。 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4546589B2 (ja) * | 1998-04-23 | 2010-09-15 | 武田薬品工業株式会社 | ナフタレン誘導体 |
ATE293102T1 (de) | 1998-04-23 | 2005-04-15 | Takeda Pharmaceutical | Naphthalene derivate ,ihre herstellung und verwendung |
EP1227086B1 (en) * | 1999-10-22 | 2006-03-29 | Takeda Pharmaceutical Company Limited | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
JP4520012B2 (ja) * | 1999-10-22 | 2010-08-04 | 武田薬品工業株式会社 | 1−置換−1−(1h−イミダゾール−4−イル)メタノール類 |
AU2015291788A1 (en) * | 2014-07-16 | 2016-11-24 | Novogen ltd | Functionalised and substituted carbazoles as anti-cancer agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5753466A (en) * | 1980-09-17 | 1982-03-30 | Dai Ichi Seiyaku Co Ltd | 2-substituted imidazole compound |
JPS60136569A (ja) * | 1983-09-21 | 1985-07-20 | イ−ライ・リリ−・アンド・カンパニ− | フルオレニルアルキルイミダゾ−ル誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
GB9310635D0 (en) * | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
WO1995004723A1 (fr) * | 1993-08-04 | 1995-02-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derive d'imidazolylalkylamine et composition pharmaceutique contenant ledit derive |
-
1996
- 1996-03-01 AU AU48439/96A patent/AU702406B2/en not_active Ceased
- 1996-03-01 HU HU9801158A patent/HUP9801158A3/hu unknown
- 1996-03-01 CA CA002213246A patent/CA2213246A1/en not_active Abandoned
- 1996-03-01 WO PCT/JP1996/000490 patent/WO1996026927A1/ja not_active Application Discontinuation
- 1996-03-01 EP EP96904295A patent/EP0820989A4/en not_active Withdrawn
- 1996-03-01 KR KR1019970705716A patent/KR19980702319A/ko not_active Application Discontinuation
- 1996-03-01 PL PL96322028A patent/PL322028A1/xx unknown
- 1996-03-01 CN CN96192265A patent/CN1177350A/zh active Pending
- 1996-03-01 NZ NZ302392A patent/NZ302392A/en unknown
-
1997
- 1997-08-29 NO NO973980A patent/NO973980L/no unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5753466A (en) * | 1980-09-17 | 1982-03-30 | Dai Ichi Seiyaku Co Ltd | 2-substituted imidazole compound |
JPS60136569A (ja) * | 1983-09-21 | 1985-07-20 | イ−ライ・リリ−・アンド・カンパニ− | フルオレニルアルキルイミダゾ−ル誘導体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0820989A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046186A1 (fr) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation |
US7183305B2 (en) | 2003-11-11 | 2007-02-27 | Allergan, Inc. | Process for the synthesis of imidazoles |
US7598394B2 (en) | 2003-11-11 | 2009-10-06 | Allergan, Inc. | Process for the synthesis of imidazoles |
US7880017B2 (en) | 2003-11-11 | 2011-02-01 | Allergan, Inc. | Process for the synthesis of imidazoles |
US8080566B1 (en) | 2008-06-11 | 2011-12-20 | Kalypsys, Inc | Carbazole inhibitors of histamine receptors for the treatment of disease |
JP2014125444A (ja) * | 2012-12-26 | 2014-07-07 | Ne Chemcat Corp | カルバゾール類の製造方法およびこの方法により製造されたカルバゾール類。 |
Also Published As
Publication number | Publication date |
---|---|
KR19980702319A (ko) | 1998-07-15 |
EP0820989A1 (en) | 1998-01-28 |
CN1177350A (zh) | 1998-03-25 |
EP0820989A4 (en) | 1998-05-06 |
CA2213246A1 (en) | 1996-09-06 |
AU4843996A (en) | 1996-09-18 |
NO973980L (no) | 1997-10-31 |
NO973980D0 (no) | 1997-08-29 |
AU702406B2 (en) | 1999-02-18 |
NZ302392A (en) | 1998-08-26 |
HUP9801158A3 (en) | 1999-11-29 |
HUP9801158A2 (hu) | 1999-08-30 |
MX9706585A (es) | 1997-11-29 |
PL322028A1 (en) | 1998-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU679119B2 (en) | Azole derivative and pharmaceutical composition thereof | |
JP4211394B2 (ja) | プロパン−1,3−ジオン誘導体 | |
AU2016204432B2 (en) | Process for making benzoxazepin compounds | |
CA2741511C (en) | Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity | |
MXPA06014131A (es) | Derivado de propano-1,3-diona o su sal. | |
WO1996026927A1 (fr) | Derives d'imidazole et composition medicinale a base desdits derives | |
WO1997000257A1 (fr) | Derives d'imidazole fusionnes et composition medicinale les contenant | |
ES2260303T3 (es) | Derivados de imidazol, metodo para su produccion, y su uso. | |
EP2638041B1 (en) | Substituted azaindazole compounds | |
WO1998037070A1 (fr) | Composes a anneaux condenses, leur procede de production et leur utilisation | |
JP3207417B2 (ja) | シクロアルキレンアゾール、その製造、これを有する製剤並びに医薬品の製造のためのその使用 | |
WO1996011195A1 (en) | Indole derivatives as 5ht1-like agonists | |
JPH11510177A (ja) | 置換1−インドリルプロピル−4−フェネチルピペラジン誘導体 | |
US6458821B1 (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
MXPA97006585A (en) | Derivatives of imidazol and medicinal composition of mis | |
JP2002241377A (ja) | イミダゾール誘導体、その製造法および用途 | |
JPH02131485A (ja) | 3−置換テトラヒドロチオピラノ〔2,3−b〕インドール誘導体及びその中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96192265.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 302392 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2213246 Country of ref document: CA Ref document number: 2213246 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1997 894447 Country of ref document: US Date of ref document: 19970819 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970705716 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/006585 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996904295 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996904295 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705716 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996904295 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970705716 Country of ref document: KR |